Detailed Narrative
Robust Q3 & 9M FY26 Financial Performance
Innova Captab reported a stellar Q3 FY26, with revenue from operations surging to ₹450.3 crores, a 42.3% year-on-year growth. For the nine months ended December 2025, revenue reached ₹1,182.2 crores, up 27.3% YoY. Profitability also advanced, with EBITDA climbing to ₹71.1 crores in Q3 FY26 (up 39.6% YoY) and maintaining margins at 15.8% for the quarter and 15.5% for 9M FY26. PAT for Q3 FY26 stood at ₹42.1 crores.
Segmental Growth: CDMO and Branded Generics
Both core business verticals demonstrated strong growth. The CDMO business generated ₹298.7 crores in Q3 FY26, an increase of 29% YoY, fueled by deeper client partnerships and new wins. For 9M FY26, CDMO revenue totaled ₹813.9 crores, growing 18% YoY. Branded generics showed even more aggressive growth, surging 79% YoY to ₹151.6 crores in Q3 FY26 and 56% YoY to ₹368.4 crores for 9M FY26, driven by geographic expansion and intensified market penetration.
Jammu Facility: Nearing Break-even and Future Potential
The new Jammu facility contributed approximately ₹89 crores to Q3 FY26 revenue, an increase from ₹60 crores in the previous quarter. Management stated that the facility is nearing break-even at the EBITDA level and is expected to make a positive contribution to both EBITDA and PAT in the next fiscal year. At optimum capacity (65-75% utilization), Jammu has the potential to generate over ₹1,400 crores in revenue.
Capacity Utilization and Expansion Strategy
Existing manufacturing facilities in Baddi, Dehradun, and Taloja are operating at a capacity utilization of 55% to 60%. These facilities still hold a growth potential of 15% to 25%. The company is focused on capacity expansion and geographical diversification to ensure sustained revenue acceleration and profitability gains, with the Jammu facility being a key part of this strategy.
API Price Environment and Export Mix
Management noted that API prices have stabilized quarter-on-quarter, though year-on-year there has been a negative impact, and future trends remain uncertain. Exports formed a healthy 35% of Q3 FY26 revenue mix and 32% for 9M FY26, underscoring strategic progress in global markets. The long-term target for the export-to-domestic revenue mix is maintained at a 35-65% ratio.
Outlook and Strategic Focus
Innova Captab is targeting an overall business growth of 20% plus for FY27. The company emphasizes its focus on innovation and research, driven by a dedicated R&D centre, to meet the needs of the changing pharmaceutical environment. Management also highlighted the importance of disciplined execution and operational efficiency to deliver sustainable margins amidst robust growth.